Endocrine Abstracts

Objective: Bicalutamide is approved as an adjuvant to primary treatments (radical prostatectomy or radiotherapy) or as monotherapy in men with locally advanced, nonmetastatic prostate cancer (PCa); however, this treatment induces gynaecomastia in most of patients, which results in treatment withdrawal. Optimal therapy for these breast events is not known so far. We conducted a meta-analysis to assess the efficacy of different treatment options for bicalutamide induced gynaecom...

Background: To evaluate outcomes and toxicities in patients with non-anaplastic thyroid cancer treated with intensity modulated radiation therapy (IMRT).Materials and methods: This was a single institution retrospective review of 18 patients with non-anaplastic thyroid cancer treated with IMRT at King Fahad Medical City between April 2005 and December 2010. The median age was 69 years. Among the 18 patients, fifteen had papillary carcinoma, two had T3 an...